population received a prescription for one of these medications in 2023
Retatrutide, often shortened to "reta", is a peptide that researchers are still testing in clinical trials
DOI: 10.1210/en.2014-1675 [Google Scholar] Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al
The hormone, called glucagon-like peptide-1, helps regulate blood sugar.by promoting the secretion of insulin
These were reflected in improvements in lipid profiles and glycemic control, with notable reductions in HbA1c and insulin requirements, although the magnitude of benefit varied by specific GLP-1 RA, dosage, and duration of follow-up
The glucagon component increases energy expenditure and fat oxidation, potentially addressing the metabolic adaptation problem from yet another angle